Sanofi (SNY) and Regeneron (REGN) to Lower Net Price of Praluent; Praluent will become Exclusive PCSK9 inhibitor Therapy on Express Scripts (ESRX) National Formulary
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced they will lower the net price of Praluent® (alirocumab) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)